Metformin and troglitazone in the treatment of female infertility associated with polycystic ovarian syndrome
Abstract
Polycystic ovarian syndrome is the most common cause of anovulatory infertility and causes menstrual disruption in 5-10% females, and is characterized by insulin resistance, hyperinsulinemia, hyperandrogenism and anovulation. Such factors are responsible for the increased miscarriage and infertility in women with PCOS. Administration of various insulin sensitizing drugs, such as metformin and troglitazone have been shown to decrease serum androgen concentrations and to increase ovulation rates, increase conception and decrease miscarriage in affected women.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.